Question
Which of the following anticancer drugs are competitive inhibitors of tyrosine kinase –
A. Imatinib and sunitinib
B. Letrozole
C. Bicalutamide
D. Fulvestrant
Show Answer
|
Correct Answer » A Explanation |
 |
Ans. is ‘a’ i.e., Imatinib and sunitinib
Molecular targeted agents
- Tyrosine kinase inhibitors
- Competitive inhibitors → Imatinib, Nilotinib, Sunitinib, Dasatinib, Erlotinib, Gefitinib, Lapatinib, Sorafenib (Remember all end with ‘ nib’).
- Monoclonal antibodies → Cetuximab, panitumumab.
- HER2/neu (ERB B2) inhibitors Monoclonal antibody – Trastuzumab.
- Targeted antibody → Gemtuzumab (anti CD-33), Rituximab (anti – CD20), Alemtuzumab (anti CD-52).
- Vascular endothelial growth factor (VEGF) inhibitor → Monoclonal antibody – Bevacizumab.
- Proteosome inhibitors → Bortezomib.
- Histone deacetylase inhibitor → Vorinostat
- DNA – methyltransferase inhibitor → 5-azacytidine, 2-deoxy-5 azacytidine.
- All – trans-retinoic acid.
- Biological response modifier – Recombinant IL-2 (aldesleukin, denileukin).